You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Wednesday, December 6, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       
       

       

       

      CME / ABIM MOC

      Addressing Key Questions in the Evolving Landscape of SARS-CoV-2 Vaccines

      • Authors: Colleen F. Kelley, MD, MPH
      • CME / ABIM MOC Released: 9/16/2022
      • THIS ACTIVITY HAS EXPIRED FOR CREDIT
      • Valid for credit through: 9/16/2023, 11:59 PM EST
      Start Activity

      Target Audience and Goal Statement

      This activity is intended for clinicians who practice in the specialties of primary care, internal medicine, infectious diseases, and obstetrics/gynecology, and anyone who is in a position to discuss COVID-19 vaccines with patients.

      The goal of this activity is that learners will be better able to discuss the evolving landscape of SARS-CoV-2 vaccines.

      Upon completion of this activity, participants will:

      • Have increased knowledge regarding the
        • Clinical relevance of the different platforms for current and emerging SARS-CoV-2 vaccines
        • Emerging clinical data for SARS-CoV-2 vaccines for primary and booster vaccination programs in adults

      Disclosures

      Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

      All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

      Disclosures for additional planners can be found here.

      Faculty

      • Colleen F. Kelley, MD, MPH

        Associate Professor of Medicine
        Emory University School of Medicine
        Atlanta, Georgia

        Disclosures

        The opinions expressed are those of Dr Kelley and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Kelley's participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.
        Colleen F. Kelley, MD, MPH, has the following relevant financial relationships:
        Research funding from: Gilead; Humanigen; Moderna; Novavax; ViiV

      Editors

      • Maria B. Uravich, BSc, ELS

        Senior Medical Education Director, WebMD Global, LLC 

        Disclosures

        Maria B. Uravich, BSc, ELS, has no relevant financial relationships.

      • Ashley Stumvoll, MRes

        Associate Medical Writer

        Disclosures

        Ashley Stumvoll, MRes, has no relevant financial relationships. 

      • Gina Montanero, PharmD

        Medical Writer

        Disclosures

        Gina Montanero, PharmD, has no relevant financial relationships.

      Compliance Reviewer

      • Lisa Simani, APRN, MS, ACNP

        Associate Director, Accreditation and Compliance, Medscape, LLC

        Disclosures

        Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

      Peer Reviewer

      This activity has been peer reviewed and the reviewer has no relevant financial relationships.

      Accreditation Statements

      Medscape

      Interprofessional Continuing Education

      In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

        For Physicians

      • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

        Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

        Contact This Provider

      For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

      Instructions for Participation and Credit

      There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

      This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

      Follow these steps to earn CME/CE credit*:

      1. Read about the target audience, learning objectives, and author disclosures.
      2. Study the educational content online or print it out.
      3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

      You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

      *The credit that you receive is based on your user profile.

      < Advances in Prevention and Management of COVID-19
      From Medscape Education Family Medicine
      CME / ABIM MOC

      Addressing Key Questions in the Evolving Landscape of SARS-CoV-2 Vaccines

      Authors: Colleen F. Kelley, MD, MPHFaculty and Disclosures
      THIS ACTIVITY HAS EXPIRED FOR CREDIT

      CME / ABIM MOC Released: 9/16/2022

      Valid for credit through: 9/16/2023, 11:59 PM EST

      processing....

      References

      1. Food and Drug Administration (FDA). Janssen COVID-19 vaccine EUA fact sheet for healthcare providers. 2022. Accessed August 12, 2022. https://www.fda.gov/media/146304/download
      2. Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency Use Authorization (EUA) of the Pfizer-Biontech Covid-19 vaccine to prevent coronavirus disease 2019 (Covid-19). 2022. Accessed August 12, 2022. https://www.fda.gov/media/153715/download
      3. Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Moderna Covid-19 vaccine to prevent coronavirus disease 2019 (Covid-19). 2022. Accessed August 12, 2022. https://www.fda.gov/media/157233/download
      4. Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine (vaccination providers) Emergency Use Authorization (EUA) of the Novavax Covid-19 vaccine, adjuvanted to prevent coronavirus disease 2019 (Covid-19). 2022. Accessed August 12, 2022. https://www.fda.gov/media/159897/download
      5. Sadoff J, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New Engl J Med. 2021;384:2187-2201.
      6. Centers for Disease Control and Prevention (CDC). COVID Data Tracker: COVID-19 Vaccinations in the United States. 2022. Accessed August 31, 2022. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-additional-dose-totalpop
      7. Park JW, et al. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17:1446-1460.
      8. Thomas SJ, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New Engl J Med. 2021;385:1761-1773.
      9. Dunkle LM, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. New Engl J Med. 2022;386:531-543.
      10. Masuda T, et al. Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: interim report of a phase I/II randomized controlled trial. Vaccine. 2022;40:3380-3388.
      11. Zhang Z, et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434-2451.e17
      12. Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Engl J Med. 2020;384:403-416.
      13. Heath PT, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New Engl J Med. 2021;385:1172-1183.
      14. Institute for Health Metrics and Evaluation (IHME). COVID-19 results briefing: United States. 2022. Accessed August 3, 2022. https://www.healthdata.org/sites/default/files/files/Projects/COVID/2022/102_
        briefing_United_States_of_America_8.pdf
      15. Andrews N, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. New Engl J Med. 2022;386:340-350.
      16. Goldberg Y, et al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. New Engl J Med. 2022;386:2201-2212.
      17. Munoz FM, et al. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004). Preprint [interim data/not peer reviewed]. medRxiv. 2022; 06.13.22276354. Published June 13, 2022. Accessed August 12, 2022 doi: https://doi.org/10.1016/j.cell.2022.05.022
      18. Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597:318-324.
      19. Dolgin E. How protein-based COVID vaccines could change the pandemic. Nature. 2021;599:359-360.
      20. Centers for Disease Control and Prevention (CDC). COVID Data Tracker. August 31, 2022. https://covid.cdc.gov/covid-data-tracker
      21. Chenchula S, et al. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol. 2022;94:2969-2976.
      22. Clarke KEN, et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies -- United States, September 2021-February 2022. Morbidity Mortal Wkly Rep. 2022;71:606-608.
      23. Marks P. Coronavirus (COVID-19) update: FDA recommends inclusion of Omicron BA.4/5 component for COVID-19 vaccine booster doses. News release. June 30, 2022.
      24. CDC. Media Statement: CDC Recommends the First Updated COVID-19 Booster. Published online September 1, 2022. Accessed September 13, 2022. https://www.cdc.gov/media/releases/2022/s0901-covid-19-booster.html
      25. Sapkota B, et al. Heterologous prime-boost strategies for COVID-19 vaccines. J Travel Med. 2021;29:taab191.
      26. Branche AR, et al. SARS-CoV-2 variant vaccine boosters trial: preliminary analyses. Preprint [interim data/not peer reviewed]. medRxiv. 2022; 07.12.22277336. Published July 12, 2022. doi: 10.1101/2022.07.12.22277336
      27. Centers for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. 2022. Accessed August 31, 2022. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#Interchangeability
      28. Dzau VJ, et al. Closing the global vaccine equity gap: equitably distributed manufacturing. Lancet. 2022;399:1924-1926.
      29. Ramakrishnan RK, et al. Unraveling the mystery surrounding post-acute sequelae of COVID-19. Front Immunol. 2021;12:686029.
      30. Singh J, et al. Evolutionary trajectory of SARS-CoV-2 and emerging variants. Virol J. 2021;18:166.
      « Return to: Addressing Key Questions in the Evolving Landscape of SARS-CoV-2 Vaccines
      CME / ABIM MOC Information
      • Print
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.